美国著名白血病CML专家对靶向药的一些回答

EHA 2011--停用二代激酶抑制剂的情况
2011-09-26 11:34:13   文字大小：【大】【中】【小】

摘要：目前，大多数停药研究都是针对服用伊玛替尼取得CMR（融合基因转阴）一段时间的cml患者。EHA 2011的这个研究中，伊玛替尼不耐受的患者后来换做二代激酶抑制剂（尼罗替尼或达沙替尼），取得CMR有一段时间，然后停药。研究目的是看他们的试验结果与只服伊玛替尼的患者有何不同。

在此研究中，12名患者（中位年龄59岁），持续服用伊玛替尼的中位时间为50个月。停药前服用二代药的中位时间为33个月，CMR持续中位时间为29个月。

停药后，其中有4名（30%）患者在6个月内失去了MMR，重新使用二代药后又迅速取得了MMR，1名患者没有失去MMR，但是两次检测失去了CMR，也重新服药。另外7名患者仍然停药，到上次随访时停药的中位时间已达11个月，维持了稳定的CMR，或者一两次检测出有微量的BCR-ABL融合基因残留。

请注意，此项研究仍处在早期研究阶段。



作者:来自法国

链接：

http://www.eventure-online.com/e ... amp;congressId=4634



Dear Group,

To-date, most studies on drug discontinuation in CML have involved patients on imatinib who achieved CMR for some time. In this study from EHA 2011, researchers have studied imatinib-intolerant patients who were subsequently switched to the second-generation TKIs (nilotinib, dasatinib) and who had CMR for some time, and then discontinued the drug. The objective was to study if differences exist with patients on imatinib-only therapy. In 12 patients (median age 59 years) who had imatinib therapy for a median period of 50 months.

30% (4/12) of patients lost MMR by 6 months. MMR was rapidly regained upon early
2G-TKI re-introduction. Seven patients remained off therapy at the last follow-up after a median of 11 months, with either a stable CMR or weakly detectable BCR-ABL transcripts on one or more occasions.

The results appear encouraging, however, the trial is still in its early stages,and we will keep an eye out for the future results. Take care.

Healing wishes,
Roy
Singapore, Asia

http://www.eventure-online.com/e ... 160137&congress\Id=4634

好像国内都没医生指导靶向用药

感谢分享 学习了